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INTRODUCTION
Breast cancer is the most common cancer and the second 
most lethal for women in the U.S. Moreover, in 2002, breast 
cancer became the most prevalent cancer in Korean women, 
comprising 16.8% of all cancers in women, as reported by Lee 
et al. [1]. The heterogeneous disease is complicated by numer-
ous, diverse, and interconnected host-tumor interactions with-
in tumor microenvironments that influence tumor fate and 
clinical outcomes. However, most of the mechanisms driving 
host cell-tumor cell interactions are still not well understood, 
particularly regarding the roles of mesenchymal stem cells 
(MSCs) in disease pathogenesis. MSCs have been shown to 
home to tumors through a number of mechanisms and both 
negatively and positively affect tumor growth and metastasis 
in animal models, as shown by Goldstein et al. [2] and Karnoub 
et al. [3]. MSCs transduced with anticancer peptides are cur-
rently being explored for their ability to inhibit tumor growth 
and progression; if tumor-supportive and off-target effects can 
be overcome, MSCs may become an important clinical tool 
for site-specific peptide delivery and inhibition of disease pro-
gression, as discussed in our previous review by Reagan and 
Kaplan [4].
The pro-apoptotic protein ApoL2/TRAIL (Apo Ligand 2, 
also termed tumor necrosis factor-related apoptosis-inducing 
ligand) displays potent anticancer effects on TRAIL-respon-
sive cancer cells, specifically those that express Death Recep-
tors 1 and 2, but not on healthy cells, described by Loebinger 
et al. [5] and Liu et al. [6]. Although TRAIL is currently in 
clinical trials for anticancer applications, one main challenge 
with this protein remains: soluble TRAIL is rapidly cleared 
from the body (half life of approximately 1 hour), shown by 
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Purpose: Tumor-specific delivery of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, 
at effective doses remains challenging. Herein we demonstrate 
the utility of a scaffold-based delivery system for sustained   
therapeutic cell release that capitalizes on the tumor-homing 
properties of mesenchymal stem cells (MSCs) and their ability   
to express genetically-introduced therapeutic genes. Methods: 
Implants were formed from porous, biocompatible silk scaffolds 
seeded with full length TRAIL-expressing MSCs (FLT-MSCs).   
under a doxycycline inducible promoter. In vitro studies with FLT-
MSCs demonstrated TRAIL expression and antitumor effects on 
breast cancer cells. Next, FLT-MSCs were administered to mice 
using three administration routes (mammary fat pad co-injec-
tions, tail vein injections, and subcutaneous implantation on 
scaffolds). Results: In vitro cell-specific bioluminescent imaging 
measured tumor cell specific growth in the presence of stromal 
cells and demonstrated FLT-MSC inhibition of breast cancer 
growth. FLT-MSC implants successfully decreased bone and 
lung metastasis, whereas liver metastasis decreased only with 
tail vein and co-injection administration routes. Average tumor 
burden was decreased when doxycycline was used to induce 
TRAIL expression for co-injection and scaffold groups, as com-
pared to controls with no induced TRAIL expression. Conclusion: 
This implant-based therapeutic delivery system is an effective 
and completely novel method of anticancer therapy and holds 
great potential for clinical applications.
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El-Deiry [7] and Kagawa et al. [8]. Some studies have addressed 
the rapid clearance by creating fusion TRAIL-human serum 
albumin proteins, which have a much longer half-life of around 
15 hours, demonstrated by Müller et al. [9], but this technique 
still provides a much shorter therapeutic window compared 
to cell-based delivery. Moreover, others (Dörr et al. [10] and Jo 
et al. [11]) have shown possible off-target toxicity in liver and 
brain from TRAIL, demonstrating the need for site-specific 
delivery. A cell-based delivery system to produce TRAIL   
continually and specifically within the tumor location would 
greatly increase the efficacy of the protein. The aim of this 
study was to deliver full length TRAIL (FLT) protein through 
TRAIL-expressing MSCs (FLT-MSCs) using a novel delivery 
approach for longer, sustained, and hence more effective  
delivery. This would greatly improve upon intravenous delivery 
by creating a much larger tumor-responsive therapeutic window. 
As shown here, our implant delivery system provides a niche 
environment for MSCs to reside and be recruited to tumors in 
response to tumor growth 
Silk is an FDA-approved biomaterial and in scaffold form 
can be easily modified in terms of size, mechanical strength, 
porosity, pore-size, and degradation time, lasting from weeks 
to years, reported by Wang et al. [12]. MSCs have been shown 
to home from subcutaneously implanted MSC-seeded silk 
scaffolds to orthotopic breast tumors by Goldstein et al. [2]. 
Zhao et al. [13] and Ali et al. [14] have recently demonstrated 
the ability to design and generate biomaterial scaffolds for cell 
delivery or to induce host immune-cell tracking and activa-
tion, but none have proposed or examined the concept of   
exogenous long-term cell delivery or niche/implant based cell 
delivery for cancer or other disease applications. Based on the 
urgent need for inventive anti-cancer strategies, the silk scaf-
fold platform was investigated, as described in this manuscript, 
for its ability to deliver therapeutic FLT-MSCs and inhibit 
breast cancer. An array of implants were created and screened 
in vitro for their ability to harbor FLT-MSCs and the most 
promising implant was selected to test in vivo in a NOD/SCID 
breast cancer mouse model. Breast cancer cells (BCCs) found 
to be TRAIL-sensitive in in vitro work were used in vivo to test 
the efficacy of therapeutic implants compared to MSC tail vein 
injections, co-injections or no MSCs and anti-cancer results 
were observed, suggesting potential for anti-cancer effects from 
these implants in humans. 
METHODS 
Cell culture
FLT-MSCs expressing GFP and TRAIL under a doxycycline-
inducible promoter were cultured as previously described by 
Loebinger et al. [15]. Briefly, the cells were grown in an expan-
sion media of alpha minimum essential medium (αMEM) 
supplemented with FBS, L-glutamine, and antibiotics. They 
were fluorescently labeled with Vybrant DiD according to 
manufacturer’s directions (Molecular Probes, Eugene, USA). 
MDA-MB-231 and MCF7 human breast cancer cell lines were 
obtained from ATCC (Manassas, USA) and cultured as recom-
mended by ATCC. MDA-MB-231 cells were engineered to 
stably express the firefly-luciferase reporter and dsRed genes 
using a lentiviral system and cultured as previously described 
by Goldstein et al. [2]. Media components were from Gibco/
Invitrogen (Grand Island, USA) unless otherwise noted.   
Human MSCs were isolated and grown in expansion media 
as previously described by Moreau et al. [16]. MSC media 
consisted of DMEM supplemented with FBS, antibiotics, and 
basic fibroblast growth factor (bFGF). MSC seeding onto scaf-
folds and differentiation in osteogenic differentiation media 
was done as previously described by Moreau et al. [16]. Osteo-
genic media consisted of α-MEM supplemented with 10% 
FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 
µg/mL fungizone, 0.01 mM non-essential amino acids, 0.05 
mM ascorbic acid, 100 nM dexamethasone, and 10 mM β- 
glycerophosphate. All cell culture was performed at 37˚C in 
5% CO2. 
Cell-specific bioluminescence (CS-BLI) assay
For CS-BLI assays, methods were performed as previously 
described by McMillin et al. [17]. 4,000 MDA-MB-231 tumor 
cells and 2,000 FLT-MSCs were co-seeded into 384 well plates 
and grown in 50 µL of media consisting of DMEM, 10% FBS, 
and 1% penicillin/streptomycin. All samples were grown and 
read in quadruplicate and bioluminescence was read at 24 
hours after seeding using an Envision plate reader (Perkin  
Elmer, Waltham, USA). 5 µL of 2.5 mg/mL luciferin was add-
ed to each well and incubated with cells for 30 minutes at 37˚C 
before reading.
Enzyme-linked immunosorbent assays (ELISAs)
ELISAs were conducted according to manufacturer’s instruc-
tions using a Quantikine
TM Human TRAIL/TNFSF10 Immu-
noassay Kit (R&D, Minneapolis, USA). 0.5×10
6 FLT-MSCs 
were used per group. FLT-MSCs were cultured in expansion 
media containing 5 µg/mL dexamethasone for 1, 2, 3, or 4 days. 
To assess how long TRAIL persists after doxycycline removal, 
FLT-MSCs were cultured in expansion media containing 5 µg/
mL doxycycline for 3 days and then withdrawn from doxycy-
cline for 1, 2, or 3 days. Cells were seeded 1 day prior to addi-
tion of doxycycline. Cell lysates were stored at -80˚C. Samples 
were normalized to a No-Dox Control group (FLT-MSCs TRAILStemCellImplantsReduceBreastCancerMetastasis 275
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grown without doxycycline) by subtraction of the average 
control values from each group.
Formation of silk scaffolds
Scaffolds were made from silk solutions (6% water-based 
silk solution or 17% hexafluoroisopropanol [HFIP]-based silk 
solution) and NaCl salt crystals (500-600 µm size) and cut into 
cylinders (6 mm diameter×4 mm height). These were seeded 
with 1×10
6 passage 4 (P4) MSCs as previously described to 
create tissue engineered (TE)-bone [16]. For in vitro screening, 
samples were differentiated in osteogenic media for 0 (unseed-
ed), 3, 4, 5, 7, 8, or 9 weeks and then re-seeded with 1×10
6 
DiD-labeled P4 MSCs. Samples were then cultured in MSC 
expansion media for 1 week and analyzed using confocal   
imaging or trypsinized to remove cells for flow cytometry.  
Results from in vitro screening demonstrated that naïve scaf-
folds, not pre-differentiated scaffolds, were best at retaining 
MSCs. Therefore, for in vivo studies, plain scaffolds were seeded 
with 1×10
6 DiD FLT-MSCs 1 day before implantation.
In vitro scaffold screening: confocal imaging and flow 
cytometry
Confocal imaging
Live-dead and CellTracker DiD fluorescence from MSCs 
on scaffolds was imaged with a Leica DMIRE2 confocal   
microscope using a 20× objective after in vitro culture for 
specified time periods. Scaffolds were removed from culture 
and stained with a live-dead kit consisting of calcein and 
ethidium homodimer to label live and dead cells green and 
red, respectively, as recommended by the manufacturer (Invi-
trogen, Grand Island, USA). DiD signal is represented with 
cyan. Image merging was done using Leica Confocal Software 
Lite. 
Flow cytometry
Cells were trypsinized and isolated from in vitro scaffold 
samples and stained for markers expressed by MSCs: CD73 
and CD90. PE-conjugated mouse anti-human CD-73 IgG1κ 
antibodies (BD Pharmingen, San Diego, USA), and FITC-
conjugated mouse anti-human CD-90 IgG1κ antibodies (BD 
Pharmingen) were used as recommended by the manufacturer. 
7AAD viability stain (BD Pharmingen) was added to each 
sample, according to manufacturer’s instructions. To block 
non-specific binding, purified human IgG (Sigma-Aldrich, St. 
Louis, USA) was added to all samples according to manufac-
turer’s instructions. Flow cytometry was conducted on a FAC-
SCalibur, data was collected using CellQuest Pro software and 
analyzed using FloJo Software (Tree Star, Ashland, USA) v. 
7.5.4. Cells were analyzed in a PBS buffer containing 0.05 nM 
EDTA, 0.5% FBS. Cells were first gated into live and dead cells 
based on 7AAD staining, and then gated based on the presence 
or absence of DiD so that only the DiD positive cells would be 
examined for CD73 and CD90. From the sub-population of 
live, DiD positive cells, the percentages of CD73 and CD90 
positive cells were calculated for each. 
Animal experiments
Animals were cared for by the Tufts University Division of 
Laboratory Animal Medicine (DLAM) Tufts Campus Animal 
Facility under federal, state, local and NIH guidelines for animal 
care. All experiments were conducted with Tufts University 
Institutional Animal Care and Use Committee (IACUC)   
approval (protocol B2010-101). NOD/SCID (NOD.CB17-
Prkdcscid) mice aged 6 to 8 weeks old were obtained from the 
Jackson Laboratory (Bar Harbor, USA) and given one of three 
treatments of MSCs (implants, tail vein injections, or co-injec-
tions) and fed with sterile water containing 0.1% sucrose with 
or without doxycycline (2 mg/mL final concentration in drink-
ing water, changed twice a week) ad libitum. Control mice 
were given tumors only (without MSCs) and were given dox-
ycycline in their drinking water. All groups consisted of 5   
animals. For the implant group, 2 FLT-MSC implants were 
implanted subcutaneously above the rotary cuff using dorsal 
incisions 2 weeks prior to tumor formation. Incisions were 
closed using a one-layer closure with skin clips, which were 
removed 10 days later. For the tail vein group, 1×10
6 DiD-
FLT-MSCs in 100 µL PBS were injected into the tail vein of 
restrained mice 10 days after tumor formation and hence the 
first data points taken for these mice were at week 2 (represent-
ing 2 weeks after tumor formation, 4 days after MSC injection). 
For the co-injection group, 5×10
5 dsRed/Luc+-MDA-MB-231 
cells were injected with 25×10
5 DiD-FLT-MSCs into mam-
mary fat pads rather than MDA-MB-231 cells alone, which 
were used to form tumors for the other groups. Control mice 
had tumor cells, but not MSCs, injected into their mammary 
fat pads. Like all other groups, they were also given doxycy-
cline in their drinking water. Table 1 summarizes the animal 
groups utilized. 
Imaging of scaffolds: in vivo experiments
Sample FLT-MSC implants were cultured and monitored   
in vivo and in vitro. In vitro samples were grown in MSC 
expansion media and examined at days 5 and 16 using live-
dead imaging as done during the scaffold screening step; live 
and dead cells are green and red, respectively. In vivo, scaffolds 
explanted from “scaffold-control mice” were embedded in 
OCT, snap frozen in acetone and dry ice, sectioned into 10 µm 
sections and imaged on a DMIRE2 confocal microscope. Scaf-276  MichaelaR.Reagan,etal.
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folds were removed 2 weeks post-implantation and 8 weeks 
post-implantation. Images made from z-stacked maximum or 
average projections.
Tumor formation
Tumors were formed by creating a ventral incision in anes-
thetized mice between the right and left fourth mammary fat 
pads and injecting 5×10
5 dsRed/Luc
+-MDA-MB-231 cells 
into the fourth mammary fat pads with (for the co-injection 
group) or without (for the implant and tail vein groups) 
25×10
5 DiD-FLT-MSCs. For tumor formation and implant 
surgeries, mice were anesthetized using isofluorane inhalation 
(1-3%) and the day of tumor formation was considered day 0 
of in vivo studies. Cells were injected in 20 µL of Matrigel (BD 
Biosciences, San Jose, USA) using a sterile Hamilton syringe 
fitted with a 22-gauge needle. Incision sites were closed using 
a one-layer closure with skin clips, which were removed 10 
days later.
Whole animal fluorescent imaging
Six weeks post-tumor cell injection, mice were imaged for 
DiD fluorescence using the whole animal epi-illuminescence 
system from Xenogen
TM/Caliper Lifesciences IVIS Spectrum 
Imaging System (IVIS, Alameda, USA). Cy5.5 filters and a 
23235 EEV camera were used. Fluorescence values are semi-
quantitative due to light absorbance and scattering in mouse 
tissue, which varies based on location and depth of DiD MSCs.
Bioluminescent imaging (BLI): tumor growth and metastasis 
assays
Tumor growth measurements and bioluminescent detec-
tion of metastases at the study endpoint were measured at 
week 1, week 3, and week 6 using bioluminescence imaging   
of mice as previously described by Moreau et al. [16]. 100 μL 
D-luciferin (1 mg/mL solution, pH 6.5) were injected into the 
intraperitoneal cavity and mice were imaged 10 to 15 minutes 
post-injection. Average flux per mouse (ave flux) are reported 
and represent an average of the total flux in the tumor regions 
of interest (ROIs) in each mouse, averaged over all mice in the 
group. Total flux was generated from measurements of whole 
animal flux [photons/(sec*cm
2*sr)] by using automatic thresh-
olding of tumor ROIs with Living Image version 2.50 analysis 
software. Metastasis frequency was measured as previously 
described by Goldstein et al. [2].
Statistical analysis
All data are represented as mean values with error bars   
representing standard error on the mean (SEM). Statistical 
analysis was performed with GraphPad Prism version 6.00 for 
Windows (GraphPad Software Inc., La Jolla, USA). ANOVA   
was used to compare multiple groups and if ANOVA demon-
strated significance, individual comparisons were made using 
a Dunnett’s post-hoc test (for in vivo data, where n=5 mice 
per group) or Tukey’s multiple comparison test (for in vitro 
data, such as the bioluminescence in vitro assay, n=4), FACS 
expression assay for CD90 and CD73 (n=3). Symbols repre-
sent significance as follows: *p<0.001; 
†p from 0.001 to 0.01; 
‡p from 0.01 to 0.05; p>0.05, not significant.
RESULTS
Characterization of FLT-MSCs using a TRAIL ELISA assay 
demonstrated that TRAIL expression is tightly regulated by 
the doxycycline-inducible promoter (Figure 1A). Using cancer 
cell-specific bioluminescence imaging of direct co-cultures, 
the highly invasive and metastatic MDA-MB-231 cell line 
Table 1. Summary of all groups used in in vivo studies
Group name
Dox in  
drinking water? 
Tumor cells  
injected to MFP?
Treated with 
FLT-MSCs?
Route of FLT-MSC
administration
FLT-MSC  
administration time
No.  
of mice
Control Yes Yes No None injected None injected 5
Co-injections with doxycycline Yes Yes Yes Injected to MFP Simultaneously with BCCs 5
Co-injections without doxycycline No Yes Yes Injected to MFP  Simultaneously with BCCs 5
Tail vein injections with doxycycline Yes Yes Yes Injected into tail vein 10 days post-tumor 
innoculation
5
Tail vein injections without doxycycline No Yes Yes Injected into tail vein 10 days post-tumor 
inoculation
5
Implants with doxycycline Yes Yes Yes Implanted subcutane-
ously on scaffolds 
2 wk prior to tumor 
formation
5
Implants without doxycycline No Yes Yes Implanted subcutane-
ously on scaffolds
2 wk prior to tumor 
formation
5
The seven different animal groups are shown here. The positive control group contains mice with no mesenchymal stem cells (MSCs). For each full length TRAIL 
(FLT)-administration route, 5 mice were given doxycycline and 5 were not, to examine specifically the effect of tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL) expression by MSCs on tumor growth.
BCCs=breast cancer cells; MFP=mammary fat pad; Dox=doxycycline 2 mg/mL.TRAILStemCellImplantsReduceBreastCancerMetastasis 277
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Figure 1. In vitro characterization of full length TRAIL-expressing MSCs (FLT-MSCs) and their impact on breast cancer cells. (A) TRAIL protein en-
zyme-linked immunosorbent assay (ELISA) of FLT-MSCs exposed to doxycycline (denoted as “dox”) for denoted times. Cell specific-bioluminescence 
assay at 24 hours for MDA-MB-231 cell proliferation in cultures of cancer cells alone, cancer cells with FLT-MSCs, and co-culture with FLT-MSCs and 
doxycycline. Data is graphed as mean±standard error of the mean (SEM), n=3. (B) For direct co-culture imaging of FLT-MSCs and MDA-MB-231 
breast cancer cells, breast cancer cells were grown alone, or with FLT-MSCs with and without doxycycline. After 48 hours of co-culture, MDA-
MB-231 cells showed significant decreases in cell numbers in the FLT-MSC doxycycline group compared to the FLT-MSC no doxycycline group or 
the no MSC group. Statistics were done using an ANOVA and a Tukey’s multiple comparison test. *p<0.001 (mean±SEM, n=4).
TRAIL=tumor necrosis factor-related apoptosis-inducing ligand; MSC=mesenchymal stem cell; NS=not significant.
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Figure 2. Scaffold design and characterization. (A) Timeline of in vitro scaffold screening experiment. (B) Representative live-dead confocal imaging of 
water-based (WB) or solvent-based (HFIP) scaffolds. Samples were pre-differentiated for 0, 3 or 4 weeks, (denoted as 0 wk, 3 wk, or 4 wk, respec-
tively), re-seeded with DiD mesenchymal stem cells (MSCs), and imaged after 1 week. Cyan, DiD cells; Green, live cells; Red; dead cells and scaffold. 
All scale bars represent 300 µm. (C) Flow cytometric analysis of CD73 and (D) CD90 expression on DiD MSCs removed from array of scaffolds. No 
significant differences were found between groups using an ANOVA (mean±SEM, n=4).
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Figure 4. DiD full length TRAIL-expressing MSCs (FLT-MSCs) fluorescence at 6 weeks after tumor inoculation for in vivo groups with doxycycline. (A) 
Co-injection group, (B) tail vein injection group, (C) implant group, and (D) breast cancer cells alone.
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Figure 3. Silk scaffold mesenchymal stem cell (MSC) retention after in vitro and in vivo culture. Live-dead confocal images of scaffolds (A) 5 days and 
(B) 16 days post-seeding demonstrating good viability in vitro of MSCs on scaffolds. Green, live cells; Red, dead cells and silk scaffold. Frozen section 
imaged on confocal microscope of full length TRAIL-expressing MSC (FLT-MSC)-seeded HFIP scaffolds removed (C) 2 weeks post-implantation of (D) 
8 weeks post-implantation demonstrating retention of DiD FLT-MSCs in vivo. Red, DiD; Green, scaffold autofluorescence. Images made from z-
stacked maximum or average projections. All scale bars equal in size and represent 300 µm.
TRAIL=tumor necrosis factor-related apoptosis-inducing ligand.
A C B D
showed significant reductions in cell numbers in response to 
TRAIL (FLT-MSCs with doxycycline versus without doxycy-
cline groups) after 24 hours (Figure 1B). 
Water-based or HFIP-based scaffolds were seeded with MSCs 
and differentiated in osteogenic media for 6 time periods, or 
used as plain scaffolds without previous seeding (termed the 
“0 week” scaffolds) and screened for their abilities to retain 
MSCs in vitro. For this, the array of differentiated scaffolds 
were seeded with a second round of MSCs (DiD-labeled 
MSCs) and examined after 1 week in vitro using confocal 
imaging and flow cytometric analysis of DiD-MSCs removed 
from scaffolds, as described by the timeline in Figure 2A. TRAILStemCellImplantsReduceBreastCancerMetastasis 279
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Confocal analysis demonstrated that “0 week” scaffolds 
(HFIP- or water-based) retained the most DiD MSCs and 
supported spreading better than all other scaffolds (Figure 
2B). Flow cytometry demonstrated no significant differences 
between implants in their ability to retain CD73 and CD90 
expression in seeded DiD MSCs (Figure 2C, D). Hence, 0 
week-HFIP implants were selected for in vivo work due to 
their long in vivo lifetime, as previously shown by Wang et al. 
[12], and their retention of DiD-MSCs. 
Next, HFIP scaffolds were seeded with FLT-MSCs and   
analyzed using live-dead analysis with confocal imaging at 5 
and 16 days post-seeding in vitro. Resulting images demon-
strated attachment, pore infiltration, and high viability of   
FLT-MSCs on the scaffolds (Figure 3A, B). Scaffolds were 
then seeded with DiD-fluorescently-labeled FLT-MSCs and 
implanted subcutaneously into NOD/SCID mice. These simi-
larly demonstrated FLT-MSC retention and pore infiltration 
after 2 weeks and 8 weeks in vivo (Figure 3C, D, respectively). 
Figure 5. In vivo tumor growth and metastasis. (A) In vivo tumor growth assessed at weeks 1, 3, and 6 for the following mouse groups with and with-
out doxycycline (Dox): breast cancer cells alone (BCCs), co-injection groups, tail vein injection groups, and Implant groups for mice. Statistics were 
done using a one-way ANOVA and a post-hoc Dunnett’s test: *p<0.001; 
†0.001<p<0.01; 
‡0.05<p<0.01. (B) Metastatic frequency (number of me-
tastases out of total samples) in mouse femurs, liver, and lungs for mice treated with doxycycline. (C) Representative Images of (B): organs positive 
(left) and negative (right) for metastasis in brain, lung, liver, and bone using unvarying settings for imaging.
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In vivo experiments were then used to evaluate the ability for 
silk scaffolds to deliver therapeutic MSCs and produce anti-
tumor effects. Three FLT-MSC delivery mechanisms were 
compared: co-injections with tumor cells, tail vein injections 
after tumor formation, and implantation on scaffolds before 
tumor formation. At 6 weeks after tumor induction, implants 
demonstrated DiD FLT-MSC retention in vivo by semi-quan-
titative whole animal fluorescent imaging (Figure 4). Results 
demonstrate that, for co-injection groups, a strong DiD MSC 
signal remained within primary tumors (Figure 4A) while for 
tail vein injection groups a weaker DiD FLT-MSC signal was 
found only within the tail (Figure 4B). Importantly, fluores-
cent DiD FLT-MSCs were still strongly fluorescent and con-
centrated on silk scaffolds in the silk implant groups (Figure 
4C, note that these mice have their dorsal side facing upwards, 
contrasting all other mice). Mice with MDA-MB-231 tumors 
alone show diffuse, background fluorescence (Figure 4D). 
Significant reductions in tumor growth in the co-injection, 
doxycycline group versus the co-injection, no doxycycline 
group were found at weeks 1, 3, 6 (Figure 5A). Tumor growth 
was also substantially inhibited in the implant groups with   
doxycycline groups compared to no-doxycycline groups at 
week 3, and in both implant groups (with or without doxycy-
cline) at week 6.
In vivo metastasis results demonstrated the ability of coin-
jection or tail vein injection with TRAIL-expressing MSCs to 
decrease bone, lung and liver metastases as compared to BCCs 
alone (Figure 5B). Therapeutic implants with TRAIL-express-
ing FLT-MSCs were able to decrease bone and lung metastasis, 
but slightly increased the frequency of liver metastasis (Figure 
5B). Metastasis was assessed by bioluminescent imaging and 
representative positive and negative organs are shown in Figure 
5C. The cell-based peptide delivery system described herein 
capitalizes on innate tumor-homing and genetic modification 
technologies involving the production of anticancer proteins 
and inducible promoters. The system decreased tumor growth 
and bone and lung metastasis in a xenograft mouse breast 
cancer model. 
DISCUSSION
Implantation of therapeutic MSCs on a biocompatible   
implant is a translatable technology for long-term tumor   
prevention or treatment. In contrast, intravenous or intratu-
moral injection of FLT-MSCs is not clinically translatable as 
most primary breast tumors are removed once detected and 
intravenous delivery leads to rapid clearance. Therefore, the 
success of the silk implants at inhibiting primary tumor growth 
and metastasis is crucial as a first step towards development of 
an innovative new clinical delivery method. Moreover, these 
studies lay the groundwork for investigations into many other 
types of scaffold or implant delivery systems. Silk was utilized 
because it offers no cell-specific instructions and thus fosters 
retention of stem-like features for MSCs. Silk degradation   
byproducts are noninflammatory and the slow degradation rate 
of silk scaffolds, which can be specifically tuned by different 
formation processes, creates a stable, three dimensional niche 
for long-term MSC retention that can be degraded in a con-
trolled, predictable manner, described by Wang et al. [12]. In 
addition, the implants can be designed to deliver other types of 
factors either through cells on silk implants or directly attached 
to the silk, such as immunostimulatory factors to generate an 
immunotherapeutic response against tumors. Growth factors, 
binding motifs chemically-coupling or embedded, or other 
ECM components (genetically, as composites, or as coatings), 
can also be coupled to silk, described by Moreau et al. [16], 
Bhardwaj et al. [18], and Lü et al. [19]. 
The trends of our results at week 3 and 6 show drastic,   
decreases in tumor burden resulting from both TRAIL implants 
and co-injection doxycycline groups. At later time points, the 
trend is also found in the tail vein doxycycline groups, by 6 
weeks the tail vein injected mice also benefited from TRAIL-
MSCs. This lag in efficacy may be due to the fact that FLT-
MSCs are administered after tumor formation for the tail vein 
injection group as opposed to before or during tumor forma-
tion for implant and co-injection groups, respectively. Impor-
tantly, bone and lung metastases were decreased with the   
doxycycline tail vein, co-injection and implant groups, although 
liver metastasis was slightly increased for the implant group, 
suggesting that not all sites of metastasis may be equally   
affected by TRAIL therapy. We are not certain why liver   
metastasis increased in the tumor implant groups, while bone 
and lung metastasis decreased, but it is possible that this is  
due to more lung and bone homing and less liver homing by 
FLT-MSCs. This should be explored with future studies.   
Specifically, future work should examine biodistribution of 
FLT-MSCs, perhaps by using Renilla-luciferase labeled MSCs 
and firefly-luciferase labeled BCCs, as shown previously by 
Wang et al. [20]. Although our previous work demonstrated 
tumor-homing of MSCs from silk implants [2], the in vivo 
experiments performed herein did not allow for tracking of 
FLT-MSCs. This is due to the fact that the DiD is not a stable 
dye within the cells and can both leak out and decrease in  
signal as cells reproduce. MSCs can also differentiate into a 
number of different cells within tumors, such as pericytes,   
fibroblasts, chondrocytes, adipocytes, and osteoblasts, among 
many other cell types, as described by Wang et al., making 
them impossible to accurately identify without certain gene TRAILStemCellImplantsReduceBreastCancerMetastasis 281
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labeling [20]. Bioluminescent labeling would allow for the most 
sensitive, non-destructive optical tracking and hence would be 
useful in future studies to overcome this current limitation. 
In sum, we have demonstrated the ability for therapeutic 
MSCs to significantly decrease tumor growth when adminis-
tered via a silk implant. It remains to be determined if a leaky 
TRAIL promoter or a TRAIL-independent mechanism is  
responsible for the decrease in tumor growth found in the no-
doxycycline TRAIL Implant group.
Importantly, we found that co-injections of FLT-MSCs also 
produce statistically significant reductions in tumor burden in 
the mice. Although local therapies, such as tumoral injections, 
here modeled with co-injections, may be utilized to treat   
unresectable tumors, the majority of breast tumors are resect-
able. Still, for unresectable tumors, such as gliomas, direct   
intratumoral injection of TRAIL-MSCs may hold great poten-
tial. In breast cancer, the co-injection model, though useful for 
interpreting direct FLT-MSC/cancer cell interactions, is not a 
practical delivery system applicable to most patients. More-
over, many life-threatening tumors occur at multiple, distant 
locations that require systemic treatment and may occur years 
after primary tumor removal; in fact, 90% of patients die due 
to metastasis, based on work by Weigelt et al. [21]. Therefore, 
the implant system holds potential as a clinically viable thera-
peutic approach, able to deliver MSCs throughout the body 
over a long time period (as opposed to intravenous MSC  
injections where MSCs are trapped in the lungs and quickly 
cleared from the body, shown by Lee et al. [22]). This implant-
based delivery is a Trojan-horse delivery method where MSCs 
are innately co-opted into malignancies, as shown by Gold-
stein et al. [2]. Here we have shown functional evidence for 
these implants to distribute anticancer peptides through FLT-
MSCs to inhibit tumor growth. The ability to deliver these 
peptides in a controlled manner, using antibiotic-sensitive 
promoters, allows for the accumulation of MSCs within tumors 
before peptide expression, decreasing potentially serious off-
target effects. However, MSCs can also display tumor support-
ive properties, notably, inducing chemotherapy resistance. 
The factors that determine MSC tumor support or inhibition 
are mainly unknown and must be elucidated before the use of 
anticancer MSCs becomes widespread, based on reports by 
Roodhart et al. [23] and a review from Reagan and Kaplan [4]. 
Using peptides such as TRAIL that typically affect only trans-
formed cells further localizes the treatment specifically to  
targeted areas and tilts the scale of MSC influence towards 
cancer-killing rather than cancer-supporting. 
Our breast cancer growth model is orthotopic (within the 
mammary fat pad) and humanized (utilizing human cells), 
creating a useful, translational model. However, the xenograft 
model progresses quickly with metastases arising within weeks 
of tumor cell injection. Hence, the time-scale of the model   
inaccurately represents the slower progression seen in most 
patients. Compared to tail vein delivery, implants showed   
better, longer-term MSC retention, as evidenced by the whole 
animal fluorescence imaging, suggesting that scaffolds are an 
effective administration route over a long disease course.  
Future studies using mouse models with immune-competent 
mice would also be beneficial as a more realistic model for   
effects in humans.
Cellular targets of TRAIL are currently under heavy investi-
gation, with the goal of elucidating the best clinical subgroups 
for TRAIL therapy and the complete mechanism of TRAIL-
induced apoptosis, demonstrated by work by Soria et al. [24]. 
Our experiments demonstrated TRAIL insensitivity in MCF-
7 (of luminal A subtype) and SUM1315 (of an intermediate 
epithelial/mesenchymal phenotype; positive for vimentin, 
negative for cytokeratin 5/6) but sensitivity in MDA-MB-231 
(basal subtype) cells (data not shown). This finding is corrob-
orated by recent evidence of TRAIL specificity for the cancer 
stem cell subpopulation by Loebinger et al. [5], and provides 
optimism for TRAIL treatment specifically for highly invasive, 
chemoresistant/hormone therapy resistant cancers. 
The implant system may prove useful in many stages of 
cancer progression ranging from pre-diagnosis, for initial   
detection and treatment in high-risk patients, to post-surgical, 
as adjuvant therapy to inhibit distant metastases. Therapeutic 
implants, here TRAIL-expressing MSC-seeded silk scaffolds, 
comprise a novel, translatable technology with great potential 
to treat primary or metastatic tumors effectively. Future pro-
totypes may demonstrate their ability to harbor cells that can 
survey the body for cancer and kill cancer cells before tumors 
are even clinically detectable. By capitalizing on the various 
methods of mesenchymal stem cell tracking in vivo, such 
implants may become both diagnostic and therapeutic tools 
that bridge prevention and treatment of malignancies. 
In summary, we have found that silk scaffolds delivering 
MSCs that overexpress TRAIL can reduce primary tumor size 
and bone and lung metastasis. This suggests that anti-cancer 
implants may hold great therapeutic potential for breast cancer 
and other cancer patients.
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